Cough Suppressant Drugs Market- Insights
The classification of Cough Suppressant Drugs is based on their ability to reduce coughing in animal models that lack airway pathophysiology. This classification is not comprehensive and includes many cough suppressants that also decrease cough sensitivity in healthy individuals. Cough suppressants are recommended only when they have been shown to be effective in double-blind, placebo-controlled studies in humans with respiratory pathology.
Benzoic acid esters are anesthetics used to suppress cough reflexes. They should never be taken long-term. They work on the medullar part of the brain and cause alterations in brain function. Benzoic acid esters may also cause other effects. If used long-term, they can alter brain function. Therefore, patients should always consult their physician before taking these drugs.
To Get Free Covid-19 Impact PDF Brouchure of this Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2427
Continuous approvals and launch of new cough suppressant drugs and high prevalence of cough is projected to drive the market growth
For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.
Growing prevalence of cough is again projected to be a major factor for increasing demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.
The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2017 and is expected to witness a CAGR of 3.7% during the forecast period (2018 – 2026).
North America is expected to hold leading position, due to frequent approvals of new cough suppressant drugs by FDA
North America cough suppressant market is expected to show good growth over the forecast period, due to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.
Key players in the market are involved in strategic mergers and partnerships, in order to develop, produce, and sell novel cough suppressant drugs and to gain major market share.
To Get more information Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2427
For instance, in 2015, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare (a part of Pfizer Inc.). According to the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin Brand. In exchange, Tris will provide the U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation to Pfizer Consumer Healthcare and Tris will receive an upfront payment, milestone payments, and sales-based royalties.
Various new players are entering market by adopting growth strategies such as partnership. For instance, in November 2018, Aytu BioScience, Inc., a specialty pharmaceutical company, entered into the cough suppressant drugs market with an exclusive license of FDA-approved Tuzistra XR from Tris Pharma Inc. Along with Tuzistra XR, Aytu BioScience, Inc. also has a licensed complementary antitussive product with pending FDA approval.
However, strict regulations against the use of cough suppressant is projected to affect the global cough suppressant drugs market growth over the forecast period.
For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.
In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment drugs. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.
Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/2427
Table of Contents
- Research Objectives and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Type
- Market Snippet, By Product Type
- Market Snippet, By Age Group
- Market Snippet, By Dosage Form
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Novel Product Launch/Approval
- Merger-Acquisition Scenario
- PEST Analysis
- PORTER’s Analysis
- Regulatory Scenario
- Reimbursement Scenario
- Epidemiology
- Market Dynamics
- Global Cough Suppressant Drugs Market, By Disease Type, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Dry Cough
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Wet Cough
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Cough Suppressant Drugs Market, By Drug Type, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Dextromethorphan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Codeine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Noscapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Butamirate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Benzonatate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Pholcodine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Cough Suppressant Drugs Market, By Product Type, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Over-the-counter (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Prescription Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Cough Suppressant Drugs Market, By Age Group, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Cough Suppressant Drugs Market, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/cough-suppressant-drugs-market-to-surpass-us-15188-mn-threshold-by-2026-1248
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837